Corynebacterium Amycolatum: Characteristics, Pathogenesis, and Treatment

Corynebacterium amycolatum is a gram-positive bacterium that lives harmlessly on human skin most of the time but can cause serious infections when the opportunity arises, particularly in people with weakened immune systems or implanted medical devices. For decades it flew under the radar, routinely misidentified in clinical laboratories as the closely related Corynebacterium xerosis, which meant its true role in human disease went largely unrecognized. What makes C. amycolatum especially concerning today is the frequency with which clinical isolates turn out to be resistant to most common antibiotics, leaving clinicians with a shrinking menu of reliable treatments.

A Corynebacterium Without Its Signature Coat

Most members of the genus Corynebacterium carry corynomycolic acids in their cell walls, a waxy outer layer that is something of a hallmark for the group. C. amycolatum breaks the mold: it lacks these mycolic acids entirely, which is actually where the “amycolatum” in its name comes from. Despite missing that waxy coat, researchers have found that C. amycolatum still manages to maintain limited permeability across its cell wall. A study published in Biochimica et Biophysica Acta identified a cation-selective channel protein embedded in the cell wall that appears to regulate what gets in and out, compensating to some degree for the absent mycolic acids.¹ This structural quirk has practical consequences: the absence of mycolic acids changes how the organism shows up on lab tests and influences which staining and biochemical methods can identify it correctly.

Decades of Mistaken Identity

One of the most striking aspects of C. amycolatum’s story is how consistently it was misidentified. A landmark study examined 25 clinical isolates that had been labeled as Corynebacterium xerosis and found, through detailed chemical and genetic analysis, that most of them were actually C. amycolatum.² The authors went further, suggesting that the majority of strains reported in the published literature as C. xerosis were probably misidentified too. This matters because if clinicians believed they were dealing with one species when they were actually dealing with another, the treatment choices, resistance profiles, and epidemiological tracking were all based on the wrong organism.

The confusion persisted for years because standard biochemical tests used in most clinical microbiology laboratories simply could not distinguish the two species reliably. Newer technologies have helped considerably. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, known in labs as MALDI-TOF MS, has proven to be a fast and accurate way to sort out Corynebacterium species. One evaluation of 92 clinical Corynebacterium isolates found that 87% yielded scores high enough for reliable identification, and all of those were correctly assigned to the species level, with only one pair of closely related species causing any confusion.³ A separate study comparing MALDI-TOF against conventional biochemical methods found an 89% correlation between the two, confirming the newer technology as a rapid and dependable tool for clinical labs.⁴ In a neonatal sepsis case, MALDI-TOF identified C. amycolatum from blood cultures with 99.9% confidence, enabling clinicians to adjust antibiotic therapy quickly.⁵

The shift from routine biochemical panels to MALDI-TOF and gene sequencing means that C. amycolatum infections are now being caught more often and reported more accurately. The practical takeaway for clinicians is that any isolate historically labeled as C. xerosis should be treated with suspicion. Labs that have not adopted MALDI-TOF or molecular identification methods may still be misclassifying this organism.

From Skin Commensal to Opportunistic Pathogen

C. amycolatum is part of the normal skin flora.⁶ In a healthy person, it sits quietly on the skin surface and does not cause trouble. Non-diphtherial Corynebacterium species as a group have traditionally been dismissed as contaminants when they appear in clinical cultures, often labeled “diphtheroids” and ignored.⁷ That reflexive dismissal has meant C. amycolatum infections were likely underdiagnosed for years, compounding the identification problems described above.

The organism tends to become a pathogen when given an entry point and a host whose defenses are compromised. Implanted devices like central venous catheters, prosthetic joints, and orbital implants create surfaces where bacteria can adhere and form biofilms, protected from both the immune system and antibiotics. Immunosuppression from chemotherapy, severe blood disorders, or chronic diseases like diabetes lowers the body’s ability to keep skin commensals in check. When these factors align, C. amycolatum can invade deeper tissues or the bloodstream.

A pan-genomic analysis of C. amycolatum strains shed light on the genetic underpinnings of this transition from harmless colonizer to pathogen. The study found an open pan-genome, meaning the species readily acquires new genes, with roughly half of its gene families belonging to its core genome and the other half split between accessory and unique genes. Importantly, the researchers found genomic evidence for extensive acquisition of antimicrobial resistance genes through mobile genetic elements called genomic islands.⁸ In other words, the species is not just passively present on human skin; it is actively picking up new genetic tools from its environment, including the tools to resist the drugs used against it.

Clinical Infections and Who Gets Them

The range of infections linked to C. amycolatum is wider than most clinicians might expect from a “skin commensal.” Reported cases span multiple organ systems and clinical settings:

Skin and soft tissue: Subcutaneous abscesses have been reported in severely immunocompromised patients, such as those with aplastic anemia.⁶ Breast infections (mastitis) have also been documented in otherwise immunocompetent women.⁷
Bloodstream infections: Bacteremia, including in neonates, has been confirmed with molecular identification.⁵
Endocarditis: Infection of the heart valves has been reported, though rarely. One case was successfully treated with a combination of daptomycin and rifampicin.⁹
Eye infections: An orbital implant infection involved pure isolation of C. amycolatum from a patient’s prosthetic eye socket with chronic discharge.¹⁰ A corneal ulcer in an older patient with diabetes was also attributed to the organism, apparently the first reported case of its kind.¹¹
Device-related infections: Central venous catheter infections in pediatric oncology patients have been documented, with multiresistant C. amycolatum isolated from the catheter lines.¹²

Interestingly, the pediatric oncology study found that invasive corynebacterial infections were statistically independent of factors like age, gender, specific underlying disease, and even the presence of neutropenia.¹² That result challenges the simple assumption that only profoundly immunocompromised patients are at risk. Having an indwelling catheter or prosthetic device may be a more important risk factor than the degree of immune suppression alone, though the number of patients studied was small enough that broader conclusions should be drawn cautiously.

A Resistance Problem That Limits Treatment Options

The most clinically significant feature of C. amycolatum is how resistant it tends to be. This is not a minor inconvenience; many isolates are resistant to the majority of antibiotics that would normally be considered for gram-positive infections. In a Romanian study of clinical Corynebacterium isolates, six out of seven C. amycolatum strains were resistant to eight of the eleven antibiotics tested, and one strain was resistant to nine of eleven.¹³ The affected drug classes include beta-lactams, macrolides, clindamycin, aminoglycosides, quinolones, and rifampicin.

Several specific resistance mechanisms have been identified:

Fluoroquinolone resistance: Double mutations in the gyrA gene, typically at amino acid positions 87 and 91, confer high-level resistance to fluoroquinolones like ciprofloxacin and levofloxacin.¹⁴ Novel gyrA mutations conferring high-level quinolone resistance have also been reported in bloodstream isolates.¹⁵
Macrolide and clindamycin resistance: A large study of 254 clinical Corynebacterium strains found the MLS(B) resistance phenotype, which confers resistance to macrolides, lincosamides, and streptogramins, in the majority of isolates. This resistance was driven by the erm(X) gene in 171 of 186 resistant strains.¹⁶
Beta-lactam resistance: A penicillin-binding protein called Pbp2c has been linked to high-level beta-lactam resistance in Corynebacteriaceae. The gene encoding Pbp2c is present in resistant strains but absent from susceptible ones, and it confers resistance to all beta-lactam antibiotics tested, including carbapenems, which are often considered drugs of last resort. In C. amycolatum specifically, the detection of this inducible resistance can require up to 48 hours of incubation in the lab, meaning it could be missed if cultures are read too early.¹⁷

The genomic analysis mentioned earlier supports the picture: C. amycolatum’s open pan-genome and its tendency to pick up resistance genes through genomic islands mean the species is continually expanding its resistance toolkit.⁸ This is not a static problem; it is likely getting worse over time as antibiotic pressure in hospitals selects for the most resistant strains.

What Still Works and How Treatment Decisions Are Made

Given the breadth of resistance, vancomycin has become the most dependable option for serious C. amycolatum infections. In the multicenter study that evaluated daptomycin resistance across Corynebacterium species, all isolates displayed susceptible values to vancomycin and the related lipoglycopeptide telavancin, both before and after exposure to daptomycin.¹⁸ This consistency makes vancomycin the go-to drug when a multidrug-resistant Corynebacterium infection is confirmed or suspected.

Daptomycin is sometimes used as an alternative, and the endocarditis case mentioned earlier was successfully treated with daptomycin plus rifampicin.⁹ However, there is a significant caveat: daptomycin nonsusceptibility emerged in C. amycolatum and eleven other Corynebacterium species when isolates were exposed to daptomycin in laboratory testing, with nonsusceptibility detected in roughly a third of all isolates tested across species.¹⁸ The rapidity with which this resistance can develop means daptomycin should not be used casually, and susceptibility should be monitored if treatment extends beyond a short course.

Not every C. amycolatum isolate is a multidrug-resistant nightmare. The neonatal sepsis case, for example, involved a strain that was susceptible to penicillin, cephalosporins, and vancomycin, though it was resistant to ciprofloxacin, clindamycin, and erythromycin. The infant was treated first with ampicillin and cefoperazone/sulbactam, then switched to ceftazidime based on susceptibility results, and recovered well.⁵ This illustrates why susceptibility testing is not optional for this organism. The resistance profile varies so much between strains that empirical therapy based on assumptions about what “most” isolates are resistant to can either over-treat a sensitive strain with a potent last-resort drug or under-treat a resistant one with an agent that will not work.

One practical complication for labs: the inducible beta-lactam resistance mediated by Pbp2c may not show up on standard susceptibility testing if the culture is read at 24 hours. The finding that C. amycolatum may require up to 48 hours of incubation for this resistance to become apparent¹⁷ means a strain could initially appear susceptible to a beta-lactam antibiotic when it is not. This is exactly the kind of subtle pitfall that can lead to treatment failure if the lab is not alert to it.

When the Lab Finds It, Should You Treat It?

A perennial challenge with skin commensals is distinguishing genuine infection from contamination. If C. amycolatum shows up in a single blood culture bottle, it may represent nothing more than a skin organism that hitched a ride during the blood draw. Clinical context is everything. Multiple positive cultures from the same site, growth in more than one blood culture set, the presence of signs of infection (fever, elevated inflammatory markers, local inflammation), and an identifiable risk factor like a central line or prosthetic device all tip the balance toward treating. In the absence of those signals, many infectious disease specialists would recommend watchful waiting and repeat cultures rather than jumping to vancomycin.

The historical tendency to dismiss diphtheroids as contaminants works against patients in cases where C. amycolatum is genuinely causing disease. Clinicians now need to hold two ideas in tension: this organism is usually harmless, and it is capable of causing real harm when given the chance. The improved identification methods available today at least ensure that when C. amycolatum does appear in cultures, it is recognized correctly rather than filed away under the wrong species name.

C. amycolatum in Animals and the Zoonotic Question

The clinical relevance of C. amycolatum extends beyond human medicine. A study of coryneform bacteria isolated from sows with urinary tract infections and metritis found C. amycolatum alongside C. diphtheriae and C. confusum. All of the porcine Corynebacterium strains tested showed concerning resistance profiles, with high minimum inhibitory concentrations against macrolides, lincosamides, tetracyclines, and quinolones.¹⁹ The authors flagged the isolation of known zoonotic Corynebacterium species from commercial swine as a potential concern for farmers and others in close contact with livestock.

The resistance patterns in the animal isolates mirrored the patterns seen in human clinical isolates, which raises the question of whether resistance genes are being passed between animal and human reservoirs. High antibiotic usage in both veterinary and human medicine likely contributes to this shared resistance landscape. For someone working with livestock who develops a skin or soft tissue infection that turns out to involve Corynebacterium, the possibility of encountering a multidrug-resistant strain is real and relevant. Though direct animal-to-human transmission of C. amycolatum has not been firmly established in published studies, the overlap in species and resistance profiles between animal and human isolates suggests the risk is not purely theoretical.